{"id":56250,"date":"2023-04-26T17:03:09","date_gmt":"2023-04-26T15:03:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/"},"modified":"2023-04-26T17:03:09","modified_gmt":"2023-04-26T15:03:09","slug":"beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/","title":{"rendered":"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting"},"content":{"rendered":"
\n

\nEarly-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor<\/i> BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab<\/i><\/p>\n

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASCO23<\/a>–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), <\/b>a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago, June 2-6, 2023.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cOur accepted data presentations at ASCO demonstrate the resolve and productivity of BeiGene\u2019s R&D team in our drive to improve treatment outcomes and access for patients worldwide,\u201d said Lai Wang, Ph.D., Global Head of R&D at BeiGene. \u201cWe look forward to joining the oncology community in Chicago and sharing progress as we continue to advance our rich pipeline of first-in-class and potentially best-in-class programs.\u201d<\/p>\n

\nData to be presented at ASCO include:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nAbstract Title<\/b><\/p>\n<\/td>\n

\n

\nAbstract #<\/b><\/p>\n<\/td>\n

\n

\nPresentation Details<\/b><\/p>\n<\/td>\n

\n

\nLead Author<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nSolid Tumors<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nResults from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2 amplified Biliary Tract Cancer<\/p>\n<\/td>\n

\n

\n4008<\/p>\n<\/td>\n

\n

\nOral presentation: Gastrointestinal Cancer\u2014 Gastroesophageal, Pancreatic, and Hepatobiliary<\/p>\n

\n\u00a0<\/p>\n

\nFri., June 2,<\/p>\n

\n2:45-5:45 p.m. CT<\/p>\n<\/td>\n

\n

\nShubham Pant<\/p>\n<\/td>\n<\/tr>\n

\n

\nA phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors<\/p>\n<\/td>\n

\n

\n2574<\/p>\n<\/td>\n

\n

\nPoster presentation: Developmental Therapeutics\u2014Immunotherapy<\/p>\n

\n\u00a0<\/p>\n

\nSat., June 3,<\/p>\n

\n8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nJayesh Desai<\/p>\n<\/td>\n<\/tr>\n

\n

\nZanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a Phase Ib\/II study<\/p>\n<\/td>\n

\n

\n1044<\/p>\n<\/td>\n

\n

\nPoster presentation: Breast Cancer\u2014Metastatic<\/p>\n

\n\u00a0<\/p>\n

\nSun., June 4, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nXiaojia Wang<\/p>\n<\/td>\n<\/tr>\n

\n

\nTislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 European\/North American subgroup<\/p>\n<\/td>\n

\n

\n4082<\/p>\n<\/td>\n

\n

\nPoster presentation: Gastrointestinal Cancer\u2014Gastroesophageal, Pancreatic, and Hepatobiliary<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nArndt Vogel<\/p>\n<\/td>\n<\/tr>\n

\n

\nImpact of risk factors on overall survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab<\/p>\n<\/td>\n

\n

\n4083<\/p>\n<\/td>\n

\n

\nPoster presentation: Gastrointestinal Cancer\u2014Gastroesophageal, Pancreatic, and Hepatobiliary<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nMasatoshi Kudo<\/p>\n<\/td>\n<\/tr>\n

\n

\nAdvanTIG-105: phase 1b dose-expansion study of ociperlimab + tislelizumab with chemotherapy in patients with stage IV gastric\/gastroesophageal adenocarcinoma<\/p>\n<\/td>\n

\n

\n4028<\/p>\n<\/td>\n

\n

\nPoster presentation: Gastrointestinal Cancer\u2014Gastroesophageal, Pancreatic, and Hepatobiliary<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nSe Hyun Kim<\/p>\n<\/td>\n<\/tr>\n

\n

\nHematology<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nA phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies<\/p>\n<\/td>\n

\n

\n7558<\/p>\n<\/td>\n

\n

\nPoster presentation: Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nCaixia Li<\/p>\n<\/td>\n<\/tr>\n

\n

\nFirst interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed\/refractory diffuse large B-cell lymphoma<\/p>\n<\/td>\n

\n

\n7557<\/p>\n<\/td>\n

\n

\nPoster presentation: Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nHuilai Zhang<\/p>\n<\/td>\n<\/tr>\n

\n

\nZanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed\/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study<\/p>\n<\/td>\n

\n

\n7545<\/p>\n<\/td>\n

\n

\nPoster presentation: Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nChristopher Flowers<\/p>\n<\/td>\n<\/tr>\n

\n

\nMAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma<\/p>\n<\/td>\n

\n

\nTPS7590<\/p>\n<\/td>\n

\n

\nPoster presentation: Hematologic Malignancies\u2014Lymphoma and Chronic Lymphocytic Leukemia<\/p>\n

\n\u00a0<\/p>\n

\nMon., June 5, 8:00-11:00 a.m. CT<\/p>\n<\/td>\n

\n

\nLoretta Nastoupil<\/p>\n<\/td>\n<\/tr>\n

\n

\nMatching-adjusted indirect comparison of zanubrutinib versus ibrutinib in relapsed\/refractory marginal zone lymphoma<\/p>\n<\/td>\n

\n

\ne19527<\/p>\n<\/td>\n

\n

\nPublication only<\/p>\n<\/td>\n

\n

\nCatherine Thieblemont<\/p>\n<\/td>\n<\/tr>\n

\n

\nComparative efficacy of zanubrutinib versus rituximab in relapsed marginal zone lymphoma: matching-adjusted indirect comparison<\/p>\n<\/td>\n

\n

\ne19526<\/p>\n<\/td>\n

\n

\nPublication only<\/p>\n<\/td>\n

\n

\nCatherine Thieblemont<\/p>\n<\/td>\n<\/tr>\n

\n

\nReal-world treatment patterns of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma in community oncology practices in the United States<\/p>\n<\/td>\n

\n

\ne19525<\/p>\n<\/td>\n

\n

\nPublication only<\/p>\n<\/td>\n

\n

\nBijal Shah<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout BeiGene<\/b><\/p>\n

\nBeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com<\/a> and follow us on Twitter at @BeiGeneGlobal<\/a>.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential for BeiGene’s programs to improve treatment outcomes and access to medicines for patients worldwide; the general future of BeiGene\u2019s pipeline and programs; BeiGene\u2019s advancement, anticipated clinical development, regulatory milestones and commercialization of tislelizumab, BGB-11417, BGB-A445, ociperlimab, zanubrutinib, and zanidatamab; and BeiGene\u2019s plans, commitments, aspirations, and goals under the heading \u201cAbout BeiGene.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, and other services; BeiGene\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; and the impact of the COVID-19 pandemic on BeiGene\u2019s clinical development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeiGene\u2019s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Kevin Mannix
\n
+1 240-410-0129
\n
ir@beigene.com<\/a><\/p>\n

Media Contact:<\/b>
Kathleen Cuca
\n
+ 1 551-222-6790
\n
media@beigene.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASCO23–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56250","6":"format-standard","7":"category-industry"},"yoast_head":"\nBeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASCO23–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T15:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230425006180\/en\/1775322\/21\/BeiGene_sunny.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting\",\"datePublished\":\"2023-04-26T15:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/\"},\"wordCount\":1050,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006180\\\/en\\\/1775322\\\/21\\\/BeiGene_sunny.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/\",\"name\":\"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006180\\\/en\\\/1775322\\\/21\\\/BeiGene_sunny.jpg\",\"datePublished\":\"2023-04-26T15:03:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006180\\\/en\\\/1775322\\\/21\\\/BeiGene_sunny.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425006180\\\/en\\\/1775322\\\/21\\\/BeiGene_sunny.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting - Pharma Trend","og_description":"Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASCO23–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-26T15:03:09+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230425006180\/en\/1775322\/21\/BeiGene_sunny.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting","datePublished":"2023-04-26T15:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/"},"wordCount":1050,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425006180\/en\/1775322\/21\/BeiGene_sunny.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/","name":"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425006180\/en\/1775322\/21\/BeiGene_sunny.jpg","datePublished":"2023-04-26T15:03:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230425006180\/en\/1775322\/21\/BeiGene_sunny.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230425006180\/en\/1775322\/21\/BeiGene_sunny.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beigene-to-highlight-broad-oncology-portfolio-at-the-2023-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56250"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56250\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}